Mark Cockett, PhD


Mark Cockett is the Chief Scientific Advisor of Exavir Therapeutics and was formerly VP and Head of Discovery at ViiV Healthcare, where Dr. Cockett was responsible for delivering new HIV drug candidates that are aligned to future medical needs into clinical development and providing research support for clinical development assets as they progressed in the clinic. Mark joined ViiV Healthcare following the acquisition of Bristol-Myers Squibb’s (BMS) HIV pipeline assets. Previously Mark was VP of Discovery Infectious Diseases at BMS, and was responsible for delivery of antiviral therapeutics into the pipeline. His team at BMS has delivered marketed products targeting HIV, HBV and HCV as well as the pipeline of HIV drugs recently acquired by ViiV Healthcare.